Health Care [ 7/12 ] | Biotechnology [ 32/75 ]
NASDAQ | Common Stock
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.14 Decreased by -22.27% | -0.13 Decreased by -7.69% |
| Aug 13, 25 | -0.14 Decreased by -16.67% | -0.12 Decreased by -16.67% |
| May 7, 25 | -0.12 Decreased by -9.09% | -0.13 Increased by +6.25% |
| Mar 5, 25 | -0.13 Decreased by -44.44% | -0.11 Decreased by -14.04% |
| Nov 7, 24 | -0.11 Decreased by -14.50% | -0.11 Decreased by -4.09% |
| Aug 12, 24 | -0.12 Decreased by -71.43% | -0.11 Decreased by -9.09% |
| May 9, 24 | -0.11 Decreased by -57.14% | -0.10 Decreased by -10.00% |
| Mar 7, 24 | -0.09 Decreased by -28.57% | -0.10 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -29.56 M Decreased by -21.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -30.40 M Decreased by -36.68% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -26.64 M Decreased by -30.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 272.00 K Increased by +N/A% | -29.04 M Decreased by -80.41% | Decreased by -10.68 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -24.25 M Decreased by -46.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.24 M Decreased by -94.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -20.35 M Decreased by -92.73% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -16.10 M Decreased by -56.30% | Decreased by N/A% Decreased by N/A% |